The potential impact of azithromycin in idiopathic pulmonary fibrosis

Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux
European Respiratory Journal 2019 53: 1800628; DOI: 10.1183/13993003.00628-2018

Figures

  • FIGURE 1
    FIGURE 1

    a) Characteristics of the idiopathic pulmonary fibrosis (IPF) subjects. Comparison of b) courses of antibiotics (p=0.0086) and c) hospital admissions (p<0.0001) before and after the use of azithromycin per patient years. FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide.

Back to top
View this article with LENS
Email
Print
Citation Tools

The potential impact of azithromycin in idiopathic pulmonary fibrosis
Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux
European Respiratory Journal Feb 2019, 53 (2) 1800628; DOI: 10.1183/13993003.00628-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To